drugset / Trial / NCT01427270

Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) for Uncontrolled Moderate - Severe Low Back Pain

NCT01427270

Phase 3 Completed 455 enrolled Purdue Pharma LP
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective is to assess the efficacy of oxycodone/naloxone (OXN) for the management of opioid-induced constipation (OIC) compared to oxycodone controlled-release tablets (OXY) in subjects with moderate to severe low back pain and OIC who require around-the-clock opioid therapy.

Timeline

Start
2011-08
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Naloxone Small molecule 5 mg Oral
Subject Naloxone Small molecule 20 mg Oral
Subject Oxycodone Other / unclassified 10 mg Oral
Subject Oxycodone Other / unclassified 40 mg Oral

Indications

No indication recorded.